Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
CA 2429460 A1 · Owner: California Institute Of Technology · Inventors: Wang, Hai U.; Anderson, David J.; Garcia-Cardena, Guillermo
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Arterial and venous smooth muscle cells are molecularly distinct from the earliest stages of angiogenesis through to adulthood. This distinction is revelated by expression on arterial cells (e.g. arterial endothelial cells arterial smooth muscle cells) of a transmembrane ligand called EphrinB2 whose , receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 genne prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover it also disrupts the remodeling of , arteries suggesting that reciprocal interactions between pre-specified arterial and venous cells are necessary for angiogenesis. Expression of EphrinB2 in arterial …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 20, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 20, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 20, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.